Avoiding Drug Resistance by Understanding Evolution of Viruses

During ACA’s 71st annual meeting, Celia Schiffer, from the University of Massachusetts, will talk about her lab’s work with virus substrate recognition as a method to avoid drug resistance. Schiffer and her team expanded their work on HIV and the hepatitis C virus to include human T-cell lymphotropic virus type 1 and SARS-CoV-2, the virus that causes COVID-19, and discovered that designing robust inhibitors to fit within the substrate envelope tips this balance toward decreasing the probability of resistance.